Clear cell renal cell cancer (CC-RCC) is a highly chemoresistant tumor characterized by frequent inactivation of the von Hippel-Lindau (VHL) gene. The prognosis is reportedly worse in patients whose tumors express immunoreactive type I insulin-like growth factor receptor (IGF1R), a key mediator of tumor cell survival. We aimed to investigate how IGF1R expression is regulated, and found that IGF1R protein levels were unaffected by hypoxia, but were higher in CC-RCC cells harboring mutant inactive VHL than in isogenic cells expressing wild-type (WT) VHL. IGF1R mRNA and promoter activities were significantly lower in CC-RCC cells expressing WT VHL, consistent with a transcriptional effect. In Sp1-null Drosophila Schneider cells, IGF1R promoter activity was dependent on exogenous Sp1, and was suppressed by full-length VHL protein (pVHL) but only partially by truncated VHL lacking the Sp1-binding motif. pVHL also reduced the stability of IGF1R mRNA via sequestration of HuR protein. Finally, IGF1R mRNA levels were significantly higher in CC-RCC biopsies than benign kidney, confirming the clinical relevance of these findings. Thus, we have identified a new hypoxiaindependent role for VHL in suppressing IGF1R transcription and mRNA stability. VHL inactivation leads to IGF1R upregulation, contributing to renal tumorigenesis and potentially also to chemoresistance.
Introduction
The von Hippel-Lindau gene product (pVHL) has a well-recognized role in the oxygen-dependent proteolysis of the a subunits of hypoxia-inducible factors 1 and 2 (HIF-1 and -2) (Maxwell et al., 1999) . pVHL is the substrate recognition component of an E3 ubiquitin ligase complex that includes elongin C, elongin B, cullin 2 (Cul2) and Rbx1/ROC1 (VCB-CUL2; Cockman et al., 2000; Ohh et al., 2000; Conaway and Conaway, 2002) . In normoxia, HIF-a subunits are hydroxylated on key proline residues, targeting them for pVHL-mediated ubiquitylation and proteasomal degradation (Ivan et al., 2001; Jaakkola et al., 2001) . In hypoxia, the absence of oxygen-dependent hydroxylation of HIF-a prolines allows HIF-a subunits to accumulate, heterodimerize with HIF1b/ARNT and translocate to the nucleus, triggering transcription of hypoxia-inducible genes, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and carbonic anhydrase 9 (CA9; Semenza, 1999; Harris, 2002) .
Inactivating VHL mutations occur in approximately 75% of clear cell renal cell cancer (CC-RCC) (Gnarra et al., 1994) , a highly vascular tumor which is characterized by extreme chemo-and radioresistance. Furthermore, 20% of CC-RCC show silencing of VHL expression by promoter methylation (Banks et al., 2006) , reinforcing the critical role of VHL in suppressing renal tumorigenesis. Functional inactivation of pVHL allows normoxic accumulation of HIF-a subunits, leading to constitutive expression of hypoxia-inducible genes including those encoding angiogenic peptides. Indeed, VHL mutation has been shown to be a critical factor in the pathogenesis of CC-RCC (Iliopoulos and Kaelin, 1997; Mandriota et al., 2002; Maranchie et al., 2002) .
The type I insulin-like growth factor receptor (IGF1R) is frequently overexpressed by human tumors, and mediates tumor cell proliferation, transformation and protection from apoptosis, including that induced by cytotoxic drugs (Baserga et al., 1997; Dunn et al., 1997; Hakam et al., 1999; Werner and Le Roith, 2000; Hellawell et al., 2002) . The IGF axis is also known to enhance the hypoxic response by activation of Akt and mitogen-activated protein kinase signaling, leading to stabilization of HIF-1a and -2a, and upregulation of VEGF (Zelzer et al., 1998; Fukuda et al., 2002; Treins et al., 2005) . The importance of IGF1R expression in RCC is indicated by reports demonstrating that positive immunohistochemical staining for IGF1R correlates with higher grade tumor, and poor prognosis even in low-stage disease (Ahmad et al., 2004; Parker et al., 2004) . In this study, we evaluated the role of pVHL as a regulator of IGF1R expression in CC-RCC. We report that pVHL can inhibit the expression of the IGF1R at both the transcriptional and post-transcriptional levels, but does not accelerate the degradation of IGF1R protein. Consistent with these findings in cultured cells, we observed significant IGF1R upregulation in clinical specimens of CC-RCC. Given the known role of the IGF axis in anchorage-independent growth, apoptosis protection and transformation (Baserga et al., 1997) , it is highly likely that these changes contribute to the tumorigenic effects of VHL loss, and potentially also to the chemoresistance that characterizes this tumor.
Results and Discussion

IGF1R protein levels are higher in RCC cells lacking functional pVHL
We began by assessing IGF1R expression in two human CC-RCC cell lines, RCC4/EV and 786-0/EV. As is common in CC-RCC, both cell lines lack functional pVHL due to a mutation in the VHL gene. As a result, there is failure of the normal process of normoxiainduced degradation of HIF subunits, leading to constitutive HIF activation. We also obtained isogenic RCC4/VHL and 786-0/VHL cell lines in which wildtype (WT) pVHL had been re-expressed (Maxwell et al., 1999) . Expression of the VHL transgene was confirmed by immunoblotting for hemagglutinin (HA)-tagged VHL ( Figure 1a) . As described previously, RCC4 cells expressed both HIF-1a and HIF-2a, while 786-0 cells expressed only HIF-2a (Maxwell et al., 1999) . HIF subunits were detected in both normoxia (20% O 2 ) and hypoxia (0.1% O 2 for 16 h) in VHL mutant RCC4/EV and 786-0/EV cells, but were detectable only in hypoxia in RCC4/VHL and 786-0/VHL cells ( Figure 1a ).
All four cell lines expressed detectable IGF1R protein, and levels were unaffected by hypoxia for 16 ( Figure 1a ) or 36 h (data not shown). There was a clear difference in levels of IGF1R protein that correlated with VHL status: RCC4/EV and 786-0/EV cells lacking a functional VHL gene had significantly higher levels of IGF1R compared to RCC4/VHL and 786-0/VHL (Figure 1a and b) . This finding accords with a previous observation that IGF1R levels were lower in cultured RCC cells expressing WT VHL; this study also showed that WT pVHL was able to inhibit IGF signaling by interacting with PKCd (Datta et al., 2000) . These VHLrelated differences in IGF1R levels are potentially important given that approximately 75% of sporadic CC-RCC harbor inactivating VHL mutations.
IGF1R expression is regulated by pVHL at the transcriptional level The next step was to understand how pVHL influences IGF1R protein levels. Hypoxia is known to regulate the expression of several IGF axis components, including IGF-I and -II and IGF-BP3 (Kim et al., 1998; Steinbrech et al., 2000; Ord et al., 2005) . However, the effect of pVHL on IGF1R expression seemed unlikely to be mediated by HIF-1a or -2a, given the absence of alteration in IGF1R levels with acute hypoxia. Compatible with this, BLAST search revealed no hypoxia-response elements in the IGF1R promoter. Second, given that the most well-characterized function of pVHL is its role as an E3 ligase in normoxia-induced proteolysis of HIF-a subunits, we considered the possibility that pVHL could influence the rate of IGF1R degradation. However, we found no evidence that the presence of WT VHL influenced IGF1R ubiquitylation or proteolysis (data not shown). We hypothesized that the effects of pVHL on the IGF1R may be exerted at the level of transcriptional or post-transcriptional regulation. In addition to its role in ubiquitylation of HIF-a subunits, pVHL is capable of repressing the promoter activities of VEGF and PDGF-B (Mukhopadhyay et al., 1997; Rafty and Khachigian, 2002) . A similar mechanism could underlie the ability of pVHL to suppress expression of the IGF1R. Therefore, we investigated whether pVHL could regulate expression of the IGF1R at the level of gene transcription, by performing quantitative reverse transcription-polymerase chain reaction (qRT-PCR) on RNA extracted from RCC4 and 786-0 cells (Figure 2a ). This revealed that steady-state levels of IGF1R mRNA were significantly lower in CC-RCC cells expressing WT VHL compared to levels in EV-transfectants (P ¼ 0.029 for RCC4, P ¼ 0.005 for 786-0). The magnitude of these differences paralleled the differences in IGF1R expression at the protein level, suggesting that this is the major route by which pVHL regulates IGF1R levels in CC-RCC cells.
As at the protein level, we found no evidence of hypoxia-induced alteration in IGF1R expression. VEGF and CA9 transcripts clearly showed the expected induction by hypoxia, confirming the ability of these cells to respond appropriately to a hypoxic stimulus (Figure 2b) .
To clarify the mechanism of IGF1R downregulation by WT VHL, assays for IGF1R promoter activity were performed using a luciferase reporter driven by a genomic fragment containing 476 nt of 5 0 -flanking sequence and 640 nt of the 5 0 -untranslated region of the rat IGF1R promoter, as used previously to analyse regulation of IGF1R expression (Werner et al., 1992) . Transfection of this construct into RCC4 and 786-0 cells revealed that IGF1R promoter activities were significantly lower in the presence of WT VHL compared with EV-transfected cells expressing only mutant inactive VHL ( Figure 2c ). These findings support the hypothesis that pVHL can negatively regulate IGF1R expression at the transcriptional level. To further verify the regulatory effect of pVHL on IGF1R expression, we induced silencing of the VHL gene in RCC4/VHL cells. Expression of HA-tagged VHL was effectively suppressed within 1-2 days after transfection, and remained low for up to six days ( Figure 3 ). VHL knockdown induced a time-dependent increase in IGF1R mRNA expression in RCC4/VHL cells, which by day 6 achieved levels comparable those in EV-transfected RCC4 cells that lack a functional VHL gene ( Figure 3a ). Similarly, there was an increase in IGF1R promoter activity in VHL short interfering RNA (siRNA)-transfected RCC4/VHL cells, reaching levels equivalent to those in EV transfectants ( Figure 3b ). The suggestion that these findings were indeed attributable to VHL knockdown was reinforced by the absence of changes in IGF1R mRNA or promoter activities following VHL siRNA transfection into RCC4/EV cells that lack functional VHL. Despite these early changes in IGF1R expression at the transcriptional level, there was no change in the amount of IGF1R protein during the first two days after transfection, but by four to six days IGF1R levels had reached levels comparable with those in EV-transfected (VHL mutant) RCC4 cells ( Figure 3c ). We have not previously observed confluence-dependent IGF1R upregulation, but excluded this possible explanation by the lack of alteration in IGF1R levels following transfection with non-silencing control duplex and grown to the same confluence as the VHL siRNA transfectants (data not shown). Next, we performed the reciprocal experiment by examining IGF1R levels and promoter activity in RCC4 cells that expressed tetracycline-inducible WT VHL (Wykoff et al., 2004) . VHL protein was detectable in RCC4 cells within six hours of doxycycline-mediated induction, and increased up to 24 h (Figure 3d ). In parallel with these changes, levels of IGF1R protein were detectably suppressed from twelve hours after doxycycline induction. Taken together, these experiments indicate that short-term manipulation of pVHL expression induced changes in IGF1R levels comparable to those seen in stably-transfected RCC4 and 786-0 cells, confirming the negative regulatory effect of pVHL on IGF1R expression.
pVHL repression of IGF1R transcriptional activity is mediated via the Sp1 transcription factor There is no evidence that pVHL can bind DNA, and its transcriptional regulatory role is most likely mediated through interaction with an intermediary transcription factor. Indeed pVHL has been shown to interact with Sp1 via a binding domain that has been localized to amino acids 92-122 of the 213-residue VHL protein, with residues 116-122 being of critical importance (Cohen et al., 1999) . This interaction allows pVHL to sequester Sp1 from the nucleus, preventing activation of the promoters of the VEGF and PDGF-B genes (Mukhopadhyay et al., 1997; Rafty and Khachigian, 2002) . The IGF1R promoter has been characterized as lacking TATA or CAAT elements; like many TATAless promoters, the proximal 5 0 -flanking region of the IGF1R gene is highly GC-rich and contains multiple Sp1 consensus-binding sites in both the 5 0 -flanking region and the 5 0 -untranslated region (5 0 -UTR) (Cooke et al., 1991; Mamula and Goldfine, 1992; Werner et al., 1992) . It is plausible that Sp1 could be implicated in pVHLinduced suppression of IGF1R expression, given that IGF1R expression is known to be regulated at the transcriptional level by the products of other tumor suppressor gene including p53 and BRCA1, via inhibition of Sp1 binding (Ohlsson et al., 1998; Abramovitch et al., 2003) .
To determine whether Sp1 plays a role in pVHLmediated suppression of IGF1R promoter activity, we first assessed whether pVHL protein can bind Sp1, as has been reported to occur following Sp1 transfection into Drosophila Schneider (S2) cells (Mukhopadhyay et al., 1997) . There was no difference in total Sp1 levels in RCC cells expressing mutant (RCC4/EV, 786-0/EV) or WT VHL (RCC4/VHL, 786-0/VHL), and co-immunoprecipitation revealed interaction between pVHL and Sp1 proteins only in 786-0/VHL (Figure 4a ) and RCC4/VHL (not shown). The low transfectability of RCC cells made it difficult to manipulate Sp1 levels and to analyse IGF1R promoter activity. Therefore we evaluated the effects of pVHL on IGF1R promoter activity in HEK293 and S2 cells. Transfection of VHL into HEK293 cells induced a dose-dependent increase in the expression of VHL protein, and decrease in the activity of the co-transfected IGF1R promoter reporter ( Figure 4b ). Next, we employed S2 cells, which lack endogenous Sp1 (Mukhopadhyay et al., 1997) , to investigate the hypothesis that sequestration of Sp1 by pVHL constitutes the mechanism of pVHL-mediated suppression of IGF1R expression. In these cells, there was negligible IGF1R promoter activity in the absence of exogenous Sp1. When S2 cells were transfected to express increasing amounts of Sp1, IGF1R promoter activity was induced, and this was dose dependent (Figure 4c ). Sp-1-induced IGF1R promoter activity was suppressed almost completely by full-length VHL, but only partially by truncated pVHL (pVHL1-115; Figure 4d ). However, it was clear that this truncated form of pVHL did possess residual repressor effects on IGF1R promoter activity, albeit significantly less effective than full-length VHL. This truncation mutant occurs naturally and prevents binding to elongin C (Mukhopadhyay et al., 1997) , but retains residues 96-115 and has been reported to possess residual transcriptional repressor activity (Cohen et al., 1999) . Consistent with a model in which VHL sequesters Sp1 to prevent IGF1R expression, pVHL-induced repression of IGF1R promoter activity could be competed out by increasing amounts of Sp1 (Figure 4e ). These data suggest that the negative regulatory effect of pVHL on IGF1R transcription is mediated largely through its interaction with Sp1. This is analogous to pVHL-mediated regulation of VEGF and PDGF expression, although the latter are also hypoxia-inducible genes that are additionally regulated via VHL effects on HIF-1a. Thus, VHL loss promotes HIF-and Sp1-mediated transcription of VEGF and PDGF upregulation, providing the stimulus for tumor angiogenesis. In contrast, VHL effects on IGF1R expression appear to be independent of hypoxia ( Figure 1 ).
Loss of pVHL increases IGF1R mRNA stability
The magnitude of the effects of pVHL on Sp1-induced IGF1R gene transcription appeared to correspond with the differences in IGF1R protein levels observed in cells that express or lack WT VHL. However, VHL has also been suggested to influence mRNA stability by influencing the binding of the Hu family RNA-binding protein HuR, which recognizes adenylate-and uridylate-rich elements (ARE) found in the 3 0 UTR (Gnarra et al., 1996; Datta et al., 2005) . The AREs are potent stimulators of the decapping and deadenylation processes required for mediating mRNA turnover in mammalian cells. Unlike other ARE-binding proteins that accelerate mRNA degradation (Gherzi et al., 2004; Raineri et al., 2004) , HuR has been shown to contribute to mRNA stability. The mechanism of this effect is still unclear, but may involve HuR-induced displacement of destabilizing ARE-binding proteins (Chen et al., 2002) . The IGF1R transcript contains a long 5 0 UTR with HuRbinding sites (Meng et al., 2005) , and it is possible that HuR may play a role in regulating IGF1R mRNA stability. Consistent with reported results (Datta et al., 2005) , we observed an interaction between pVHL and HuR in 786-0/VHL cells (Figure 5a ). To investigate the functional consequences of this interaction on the stability of IGF1R transcripts, 786-0/VHL and EVtransfected 786-0 CC-RCC cells were treated with actinomycin-D to block new transcription, and were transfected with VHL, HuR or non-silencing control siRNAs. In control-transfected 786-0/VHL cells, the half-life of IGF1R mRNA was approximately 12 h (Figure 5b ). VHL knockdown led to stabilization of IGF1R mRNA, so that only B20% had been degraded after 12 h, suggesting a half-life in excess of 24 h. Consistent with this result, assay of control-transfected 786-0/EV cells, which lack functional pVHL, revealed only 20-25% degradation of IGF1R transcripts in 12 h, again suggesting a half-life of at least 24 h. It was not possible to extend the duration of these experiments beyond 12 h due to excessive cell death as a result of actinomycin-D toxicity. In these 786-0/EV cells, HuR knockdown destabilized IGF1R mRNA to the same extent as the presence of pVHL (Figure 5b ). Overall, these findings indicate that the half-life of IGF1R mRNA was prolonged by HuR and by pVHL knockdown, consistent with a model in which HuR-induced stabilization of IGF1R mRNA is antagonized by the interaction between pVHL and HuR.
IGF1R mRNA levels are higher in clinical CC-RCC tumors than benign kidney Finally, we wished to evaluate the clinical significance of these observations by assessment of IGF1R levels in clinical specimens of CC-RCC and non-malignant kidney. In five pairs of fresh frozen tissues, the CC-RCC specimens expressed higher levels of IGF1R than in the benign tissue from the same cases (Figure 6a ). Quantification of these changes revealed that, compared with the paired benign kidney tissue, the tumors contained mean 3.370.5-fold more IGF1R protein (P ¼ 0.02). Next, we measured steady-state levels of IGF1R mRNA in clinical nephrectomy specimens, including 53 samples of CC-RCC and 33 samples of non-malignant kidney (Figure 6b ). IGF1R mRNA was detectable in all benign and malignant renal tissue samples. In contrast, IGF1R was detected by immunohistochemical staining in approximately 50% of CC-RCC by Parker et al. (2003) , reflecting differences in sensitivity of detection between the two techniques. Using qRT-PCR, we detected significantly higher levels of IGF1R mRNA in the CC-RCC tumors compared with benign kidney (Po0.001). From this cohort, we analysed 21 paired CC-RCC specimens with surrounding benign tissues together with 2 papillary RCC and paired normal kidney (Figure 6c ). In the CC-RCC group, 20 out of 21 CC-RCC specimens expressed higher level of IGF1R mRNA compared to the surrounding benign kidney. In the two cases of papillary RCC, there was no difference in levels of IGF1R mRNA in the tumors and paired benign tissues. When IGF1R expression at the RNA level was analysed by Fuhrman grade, there was a trend towards increasing IGF1R expression with increasing grade of CC-RCC (data not shown). These differences did not reach statistical significance, but are consistent with results of Ahmad et al. (2004) who measured IGF1R levels by immunohistochemistry. Given that at least 75% of sporadic CC-RCC harbor VHL mutations, it is likely that the majority of CC-RCC in our series lacked functional VHL. Furthermore, the rare cases of papillary RCC, which are not known to harbor VHL mutation, did not express higher IGF1R compared with normal kidney (Figure 6c ). Given that VHL is a known transcription regulator, these findings suggest that upregulation of the IGF1R in CC-RCC could be attributable to loss of functional VHL.
In summary, we have shown that pVHL regulates the expression of the IGF1R in human CC-RCC, by suppressing IGF1R transcription, and also by regulating the stability of IGF1R mRNA (Figure 7 ). In parallel with these in vitro findings, the IGF1R is upregulated in clinical samples of CC-RCC, where VHL is commonly inactivated by mutation. This effect on IGF1R upregulation represents a hypoxia-independent effect of VHL loss on renal tumorigenesis. Similarly, VHL was recently shown to suppress expression of JunB, and this capacity is lost in all mutated forms of VHL, including those that retain the ability to degrade HIF (Lee et al., 2005) . The IGF1R is a potent survival factor that can mediate resistance to cytotoxic drugs and irradiation (Sell et al., 1995; Macaulay et al., 2001; Rochester et al., 2005) . Given the intrinsic chemo-and radioresistance of CC-RCC, our findings suggest that strategies designed to block the function or expression of the IGF1R may be of therapeutic benefit in patients with advanced renal cancer. Maxwell et al., 1999) . These were cultured in complete medium supplemented with 0.5 mg/ml G418 (Invitrogen, Carlsbad, CA, USA). RCC4 cells that expressed a tetracycline-inducible WT VHL transgene (Wykoff et al., 2004) were cultured in DMEM with 10% tetracycline-free FCS (BD Bioscience, Bedford, MA, USA) supplemented with 1 mg/ ml G418 and 5 mg/ml Blasticidin (InvivoGen, San Diego, CA, USA). Drosophila Schneider S2 cells (ATCC CRL1963) were maintained in Schneider medium (Invitrogen) with 10% heatinactivated serum (Sigma, St Louis, MO, USA), 2 mM glutamine at 221C. All cells were free from mycoplasma contamination. Cells were cultured under normoxic conditions (5% CO 2 , 21% O 2 ) or in hypoxia (5% CO 2 , 0.1% O 2 ).
Materials and methods
Cell culture
Plasmids and siRNAs
Human IGF1R cDNA was myc-tagged at the carboxy terminus of the b subunit and expressed from pcDNA3 as described (Riedemann et al., 2007) . Drosophila Sp1 expression vector pPacSp1 was kindly provided by R Tjian (University of California, Berkeley, CA, USA) (Courey and Tjian, 1988) . Drosophila expression vectors pRact-HAdh, pRact-VHL 1-213 and pRact-VHL1-115 were gifts from HT Cohen (Boston Medical Centre, Boston, MA, USA). HEK293 and S2 cells were transfected using the calcium phosphate precipitation method (Gorman et al., 1982) . HEK293 cells were transfected with 5 mg plasmid DNA per well in 6-well plates, including 2 mg of IGF1R luciferase reporter and different amounts of Sp1 expression vector. S2 cells were transfected with 2.2-5.8 mg of plasmid DNA. The empty vectors pcDNA3, pPuc and pRactHAdh were used to normalize the total amount of DNA in transfections. This study utilized validated VHL (#8102664550) and HuR (#8100300139) siRNAs, and a nonsilencing control siRNA with the following sequence: sense strand 5 0 -UUCUCCGAACGUGUCACGUTT-3 0 , antisense strand 5 0 -ACGUGACACGUUCGGAGAATT-3 0 (all from Qiagen, Chatsworth, Valencia, CA, USA). The siRNAs were transfected using Oligofectamine (Invitrogen) as described (Bohula et al., 2003) . For IGF1R mRNA stability assays, 786-0 cells were transfected with VHL or HuR siRNAs and after 36 h were treated with 5 mg/ml Actinomycin D (Sigma) for the indicated times before total RNA was extracted using the RNeasy Mini Kit (Qiagen) and used in qRT-PCR.
Immunoprecipitation and western immunoblotting Cells were lysed with ice-cold IGF1R lysis buffer and analysed by immunoblotting as described (Bohula et al., 2003) . Immunoprecipitations were performed by adding 10 mg anti-HA monoclonal antibody (NB600-311, Novus Biologicals, Littleton, CO, USA) to 1-1.5 mg whole-cell lysate and immunoprecipitating overnight at 41C. Immunocomplexes were analysed by SDS-polyacrylamide gel electrophoresis and immunoblotting as described (Rochester et al., 2005) , using antibodies to IGF-1Rb (Cell Signaling Technology, Danvers, MA, USA), Sp1 (Santa Cruz, CA, USA), HIF-1a and HIF-2a (BD Biosciences, Bedford, MA, USA), HA (Novus Biologicals), HuR (Zymed, San Francisco, CA, USA) and b-tubulin (Sigma).
RNA extraction, reverse transcription and qRT-PCR Specimens of renal cancer and benign kidney were collected with the approval of the Oxford Regional Ethics Committee (Study 04/Q1607/96) from patients undergoing nephrectomy at the Churchill Hospital, Oxford. Tissue samples were snapfrozen in liquid nitrogen, lysed and homogenized using Lysing Matrix D (Qbiogene, Irvine, CA, USA). Total RNAs were extracted using the RNeasy Plus Mini Kit (Qiagen), and cDNA was synthesized by reverse transcription of total RNA using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). Real-time qRT-PCR was performed using primers and specific PCR probes from the Exiqon Universal Probe Library (Roche Diagnostics, Alameda, CA, USA) as described (Pfaffl, 2001; Kruhoffer et al., 2005) . The probe numbers and primer sequences (forward, reverse) were: IGF1R: probe #10, primers 5 0 -ttcagcgctgct gatgtg-3 0 , 5 0 -ggctcatggtgatcttctcc-3 0 ; VEGF: probe #22, 5 0 -cattggagccttgccttg-3 0 , 5 0 -atgattctgccctcctcctt-3 0 ; CA9: probe #73, 5 0 -tgcctatgagcagttgctgt-3 0 , 5 0 -tgggacctgagtctctgagc-3 0 ; b-actin: probe #63, 5 0 -cccagcacaatgaagatcaa-3 0 , 5 0 -cgatccacacg gagtacttg-3 0 ; Hypoxanthine: probe #73, 5 0 -tgaccttgatttattttgca tacc-3 0 , 5 0 -cgagcaagacgttcagtcct-3 0 ; flotillin: probe #61, 5 0 -ctcagcttcaccatcaaggac-3 0 , 5 0 -tcagcatctctctgcaccac-3 0 ; tyrosine 3-mono-oxygenase: probe #2, 5 0 -gcaattactgagagacaacttgaca-3 0 , 5 0 -tggaaggccggttaatttt-3 0 . The analysis was performed on the Corbett Research Rotor Gene 3000 qPCR System (Sydney, Australia) using the ABSOLUTE qPCR Master Mix (ABgene, Epsom, UK). The PCR reaction consisted of 20 ml of the QPCR Master Mix, 10 pmol of forward and reverse primers, 25 mg template cDNA and 1.25 ml PCR probe in a total volume of 25 ml. Conditions for the PCR reaction were 2 min at 501C, 10 min at 951C and then 40 cycles of 15 s at 951C and 1 min at 601C. The housekeeping genes (HKGs) were screened and selected from a panel of 12 commonly used HKGs, the reaction efficiency for each gene was calculated, and relative quantitation of expression of the gene of interest was derived as reported previously (Pfaffl, 2001; Vandesompele et al., 2002) .
IGF1R promoter assays IGF1R promoter assays used a genomic rat DNA fragment extending from nucleotides À470 to þ 640, where nucleotide þ 1 corresponds to the transcription start site of the rat IGF1R gene (Werner et al., 1994) . HEK293 and S2 cells were transfected using calcium phosphate (Invitrogen), and 48 h later cells were harvested for luciferase assay using the DualLuciferase Reporter Assay system (Invitrogen). Luciferase activities were measured using a 96-well microplate reader (Fluostar Optima, BMG Labtech, Offenburg, Germany) and expression in each experiment was normalized to co-transfected renilla luciferase.
